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Abstract: Mitomycin C (MC) is a natural product that exhibits therapeutic cancer qualities by forming interstrand crosslinks with DNA in cancer cells, therefore inhibiting replication and cell growth. However, the clinical utility of MC 
is limited because of adverse side effects. It is hypothesized that MC toxicity arises from the reduction that is required before DNA adducts are formed. Aziridinomitosenes (AZMs), compounds structurally similar to MC, are able to 
alkylate DNA without reductive activation. Most notably, our synthetic AZMs have been shown to form DNA/protein crosslinks as well as DNA interstrand crosslinks in the absence of added reductant. In order to determine the 
mechanism by which these adducts form, several analogs with varying substitution at four separate electrophilic centers are being prepared. Synthetic efforts toward a C7-alkyl substituted AZM propagates testing that may 
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•AZM 1: R1 and R2 =H
•AZM 8: R1= variable alkyl group




















































































Objective 1: Synthesize the unsubstituted AZM 1
Objective 2: Synthesize the C7 alkyl substituted AZM 8 
Overall Synthesis of AZM 1 and AZM 8
Conclusions and Future Work
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Molecular Model of DNA Interstrand Crosslink
• Mechanism begins with acid catalyzed aziridine ring opening, followed by 
DNA alkylation
• Nucleophilic addition to the C6 or C7 position ring results in a reduced 
quinone ring 
• Leucoaziridinomitosene formation prompts C10 carbamate departure, 

















































Nu = protein, then 
DNA-protein ICLs 
form
Proposed DNA  Alkylation by Aziridinomitosene 1:
Reductive and Non-Reductive Conditions
Molecular Model of  DNA Interstrand Crosslink
•H-bonds direct AZM 1 to the minor groove of 
DNA 
• AZM 1 selectively alkylates guanine bases, 
specifically 5’-d(CG) sequences
•DNA alkylation occurs at the C1 aziridine and 
C10 carbamate positions
•AZM 1 positions C6 and C7 are accessible to 














Mitomycin C         Aziridinomitosene 
(MC) (AZM 1) 
•Mitomycin C (MC) is a naturally 
occurring agent known to possess 
anti-cancer qualities
•Reductive activation of MC must 
occur before DNA alkylation
•MCs required reduction increases 
hematologic toxicity, limiting its 
clinical usefulness
•AZMs alkylate DNA similarly to 

























Cell Line (suspension) MC AZM 1 AZM 10
Jurkat (T-cell leukemia)h 1.98 24.4 0.11
YB 2/0 (B-cell leukemia)r 0.5 24.3 0.45
HL 60 (promyelocytic leukemia)h,* 0.07 2.7 0.003
* These studies were performed by Jamie Montgomery in collaboration with Dr. 
Richard Olson of MSTMRI and the Boise VA Medical Center. r = rat, h = human
•Compounds differ in substitution at four sites involved in DNA crosslink formation: C1, C6, C7,  
and C10






•AZM 1 has been previously shown to bind to DNA
•It is hypothesized that the C7 alkyl substituted AZM 8 will form DPCLs with 
depreciated efficacy because of steric constraints
•Goal 1: Complete synthesis of AZM 1
•Goal 2: Conduct synthesis for AZM 8 to investigate the role of the C7 site in DNA 
ICL formation
•Goal 3: By concurrently synthesizing AZM 1 and AZM 8, proper testing may be 

























































Reduced MC yields a 
leucoaziridinomitosene, in 
which C1 and C10 are activated 
for DNA cross-linking.
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